On October 7, 2011, the United States Preventive Services Task Force (USPSTF) released their evidence statement and grade D recommendation against prostate-specific antigen (PSA)-based prostate cancer screening.
Using a time series design, we assessed the effect of this recommendation upon evaluations for elevated PSA levels and prostate biopsies in our large urology group practice. We found that, despite a 24. 1% increase in total visits, the 32 urologists in our practice completed 16. 4% fewer evaluations for elevated PSA levels (317 fewer evaluations per month; P = . 017) and 21. 4% fewer prostate biopsies (42 fewer biopsies per month; P = . 001) in the 2 years following the USPSTF grade D recommendation.
Reviews in urology. 2015 [Epub]
Kathleen F McGinley, Gregory C McMahon, Gordon A Brown
Department of Urology, Rowan University School of Osteopathic Medicine, Stratford, NJ.